Atlas Trials

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure

Clinical trial NCT06045975 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06045975
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HCC - Hepatocellular Carcinoma
Start date
2024-03-28
Primary completion
2027-09-27
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.